Navigation Links
Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
Date:9/30/2008

PASADENA, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract from Gedeon Richter (BSE: GDRB) to provide engineering, procurement, and construction management services and validation assistance for a grassroots, multi-purpose biotechnology research & development and manufacturing facility in Debrecen, Hungary.

Officials did not disclose contract details but noted they would execute the work from their office in Milan, Italy.

Gedeon Richter, headquartered in Budapest, Hungary, is one of the largest multinational pharmaceutical companies in Central Eastern Europe and the Commonwealth of Independent States. It has a growing presence through commercial subsidiaries in key European Union countries, Asia, and the United States.

In making the announcement, Jacobs Group Vice President Robert Matha said "We are eager to help Gedeon Richter with this important project, which strengthens its commitment to biotechnology. In supporting the company's strategic goal of establishing a strong biopharma line, we also help Gedeon Richter to expand its worldwide portfolio of high value products."

Jacobs, with over 56,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2007 Form 10-K, and in particular the discussions contained under Items 1 - Business, 1A - Risk Factors, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact:

Michelle Jones

626.578.6968

(Logo: http://www.newscom.com/cgi-bin/prnh/20051021/LAJACOBSEGLOGO)


'/>"/>
SOURCE Jacobs Engineering Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
2. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
5. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
6. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
7. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
8. PLC Systems Receives Delisting Notice From American Stock Exchange
9. Nephros Receives Non-Compliance Notification from AMEX
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
Breaking Biology News(10 mins):